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This special issue of Purinergic Signalling brings together
12 peer-reviewed reviews and original research papers
presented at the first joint Italian-German Purine Club
meeting “Progress in Purinergic Receptor Pharmacology
and Function” held in Chieti (Italy), 18–20 September
2005. These contributions were selected among those
focusing on four topics that the Scientific Committee of
the Boards of the Italian and German Purine Club Chapters
recognized to be most representative of status of the art: (1)
advances in purinergic receptor structure and function, (2)
new agonists and antagonists of P1 and P2 receptors, (3)
non-adenine-based nucleotide and nucleoside signalling,
and (4) 5′-nucleotidase activity. As guest editors we deeply
appreciated the effort of all the authors who agreed to
contribute to this special issue in the hope that also non-
specialist readers can share our enthusiasm for this field of
research.
The paper by D’Ambrosi and colleagues, well represen-
tative of the topic “advances in purinergic receptor structure
and functions”, provides evidence for the formation of
P2Y4 dimers and oligomers in neuronal cells. Although it is
well established that P2X receptors as well as G protein-
coupled receptors (GPCRs) can directly associate, little is
known about P2Y receptor assembly. The results presented
in this article are of particular interest in that they may help
to explain the different biological responses often triggered
by the activation of P2Y receptors and may help to better
define the “combinatorial P2 receptor web” as recently
defined by Volontè and colleagues (2006). The articles by
Gessi and colleagues and by Dal Ben and colleagues,
epitomizing the topic “new agents and antagonists of P1
and P2 receptors”, describe novel receptor ligands for P1
receptors, with particular emphasis on A2B and A3
receptors, respectively. The former describes the effects of
novel selective ligands for A2B receptors by testing their
antagonist or inverse agonist properties on the modulation
of stimulated cAMP accumulation in HEK293 cells trans-
fected with the recombinant human A2B receptor and cells
expressing the native A2B receptor. Binding experiments
were also performed to measure the affinity of these new
ligands. These molecules might help to develop new potent
and selective tools to modulate A2B receptor function with
several important clinical applications, including type II
diabetes, Alzheimer’s disease, cystic fibrosis and asthma.
Growing interest focuses on the synthesis of selective A3
receptor ligands, given the role played by this adenosine
receptor in cell growth. The paper by Dal Ben and
colleagues shows that newly synthesised 2-phenylethyny-
ladenosine derivatives exhibited very high potency and
selectivity for the human A3 receptor subtype. In particular
the N
6-methoxy-2-phenylethynyl-5′-N-methylcarboxami-
doadenosine turned out to be the most potent and selective
agonist for this site. Binding and functional data were
confirmed by molecular modelling studies.
The article by Abbracchio and Ceruti provides a
comprehensive review on P2 receptor functions in glial
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which represent a major brain cell type, release adenosine
triphosphate (ATP) and trigger, following ATP exposure, a
calcium wave that establishes a key pathway for glia-glia
and glia-neuron interaction. The important role of P2
astrocyte receptors in CNS diseases, including neuroinflam-
mation and neurodegeneration, is also discussed. The papers
by Visentin and colleagues and by Tebano and colleagues,
along with that by Merighi and colleagues, cover the topic
“adenine-based nucleotide and nucleoside signalling”. In the
first paper the authors investigate the role of purine
nucleotides in themodulation of calcium signalling.Calcium
imaging and mRNA expression studies indicate the adeno-
sine diphosphate (ADP)-selective P2Y12 as a key calcium-
mobilizing receptor in microglial cells. In the second study
the authors followed up their previous results obtained in
the striatum to provide evidence of the occurrence of A2A/
mGlu5R functional interaction also in the hippocampus.
Besides the relevant role of this interaction in the
modulation of N-methyl-D-aspartate (NMDA)-mediated
neurotoxicity, which makes A2A receptors additional im-
portant targets for the development of new therapies for
neurodegenerative diseases, the individuation of A2A/
mGluR interplay in the hippocampus may help elucidate
the neurophysiological basis of learning and memory. The
paper by Merighi and colleagues provides novel informa-
tion on A3 adenosine receptor signalling. These authors
show that in A375 human melanoma cells the A3-mediated
inhibition of cell proliferation is linked to a complex
inhibitory link involving the PLC-PI3K-Akt system and
the ERK pathway. A better understanding of adenosine
signalling in tumor cells is of great interest for the
development of new therapeutic approaches to neoplasias.
Within the topic “non-adenine-based nucleotide and
nucleoside signalling” the papers by Pietrangelo and col-
leagues, Ballerini and colleagues and Jiang and colleagues
report intriguing observations on cell responses to guanine-
based purines. In the first article the authors report on the
role of guanosine triphosphate (GTP) in the differentiation of
rat pheochromocytoma PC12 cells and mouse skeletal
muscle C2C12 cells. In both the cell lines extracellular
GTP appears to bind to specific P2Y-like receptor(s) and to
increase intracellular Ca
2+.T h eC a
2+ rise in turn is
responsible for ERK activation and for increased expression
of myosin heavy chain (MyHC) in PC12 and C2C12 cells,
respectively, thus leading to cell differentiation. The paper by
Ballerini and colleagues shows that guanosine increases
cholesterol efflux and ApoE expression in glial cells, thus
providing evidence for a further mechanism by which this
nucleoside, by regulating astrocyte activity, may exert its
neuroprotective effects. Jiang and colleagues present data
showing that in the mouse topical application of guanosine
and inosine accelerates wound healing in excisional dermal
wounds. The mechanism seems to be distinct from those
mediated by adenosine-based purines. Similar effects were
found in genetically diabetic (BKS.Cg-m+/+leprdb) mice
which, like humans with adult-onset diabetes, have signifi-
cantly delayed wound healing. This suggests a potential
alternative approach for the treatment of wounds in several
clinical settings. The paper by Deussen and colleagues
presents data on adenosine metabolism in mouse heart. Even
though mouse heart is a pretty well-known model system in
experimental cardiology, little is known on adenosine
metabolism and transport in the heart so far. The results by
Deussen and co-workers indicate an active extracellular
adenosine production by ecto-enzymes and the presence of
membrane adenosine transporters relatively insensitive to
nitrobenzylthioinosine (NBTI). The final article by Ipata and
Tozzi shows recent studies on the structure, function and
regulation of cytosolic IMP-GMP specific 5′-nucleotidase II
(cN-II), a key enzyme involved in the modulation of uric
acid production, in the control of AMP and GMP concen-
tration, and in the purine “de novo” synthesis. These data
suggest that cN-II might also be involved in the regulation of
5-phosphoribosyl-1-pyrophosphate (PRPP) and in xantho-
sine salvage. This paper is of particular interest as a growing
number of neurological impairments seem to be associated to
misfunction of 5′-nucleotidase and related enzyme systems.
Finally, we are grateful to the Editor in Chief of
Purinergic Signalling Prof. G. Burnstock and to Springer
for their support and advice in the organization of this
special issue. A special thanks also to the Congress Co-
chairman, Prof. Peter Illes for his precious and continuous
collaboration. Sincere thanks to all the contributors and a
warm invitation to reconvene in the fall of 2007 in Leipzig
for the second joint Italian-German Purine Club meeting.
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